For lawful in-vitro, analytical and laboratory research use only. Not intended for human or veterinary use, consumption, diagnosis, treatment or disease prevention.

Triple-receptor agonism in experimental models

How affinity, potency and response are separated when one molecule is studied across three receptors.

01Three receptors, three measurement systems

The GIP, GLP-1 and glucagon receptors belong to the G-protein-coupled receptor family. Their activation can be studied using binding assays or…

02Potency does not always mean the same response

The concentration required for a defined response should not be confused with maximum response or binding affinity. Comparisons between molecules require…

03From assay to conclusion

A functional assay supports a conclusion about its specific model and endpoint. It does not alone establish behaviour in a whole…

01

Three receptors, three measurement systems

The GIP, GLP-1 and glucagon receptors belong to the G-protein-coupled receptor family. Their activation can be studied using binding assays or functional readouts such as second-messenger production. Results depend on the cell system, receptor expression and assay format.

02

Potency does not always mean the same response

The concentration required for a defined response should not be confused with maximum response or binding affinity. Comparisons between molecules require shared conditions, appropriate controls and reporting of uncertainty. Numbers from different laboratories are not automatically directly comparable.

03

From assay to conclusion

A functional assay supports a conclusion about its specific model and endpoint. It does not alone establish behaviour in a whole organism. Strong reporting states the protocol, controls, replicates and limitations before connecting the result to broader biology.

LABORATORY APPLICATION

Turning the principle into an auditable record

For a triple-agonism report, record the expression system, replicate count, normalisation basis and uncertainty interval for each receptor. Showing curves alongside summary values helps reveal unusual slopes, restricted dynamic range or instability that a single number may conceal.

01Comparing EC50 across incompatible systems
02Omitting the reference agonist
03Equating potency with maximum response

PRIMARY & OFFICIAL SOURCES

Sources and further reading

  1. 01Coskun et al. — LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist↗
  2. 02EMA / ICH Q2(R2) — Validation of analytical procedures↗

COMMON QUESTIONS

Questions specific to this topic

Do all assays measure the same event?

No. Binding, second messengers and downstream responses sit at different points in the signalling pathway.

Can values from different papers be compared?

Only with great care after comparing the system, protocol, units, controls and curve-fitting approach.

What strengthens a selectivity conclusion?

Shared conditions, adequate dynamic range, suitable controls and uncertainty reporting for each receptor.